“In a groundbreaking phase 3 ADVANCE OUTCOMES study, United Therapeutics’ investigational oral prostacyclin agonist ralinepag achieved a highly significant 55%…
“In a market where reliable cash generation separates winners from laggards, two standout stocks demonstrate robust FCF profiles, sustainable shareholder…
Cascades Inc. delivered a strong Q4 2025 performance with adjusted EBITDA up 9% year-over-year to CAD 155 million, driven by…
“As Warren Buffett steps away from the CEO role at Berkshire Hathaway after six decades, his final act as leader…
Talen Energy delivered a solid earnings performance for full-year 2025, posting Adjusted EBITDA of $1,035 million and Adjusted Free Cash…
Fidelis Insurance Holdings Limited reported impressive fourth-quarter performance for 2025, posting a combined ratio of 80.6%—a dramatic 47-point improvement from…
“Jim Cramer’s recent endorsement of Huntington Ingalls Industries (HII) as ‘the best thing we have when it comes to the…
“The Canadian Investment Regulatory Organization (CIRO) plays a pivotal role in maintaining orderly markets by imposing trading halts on individual…
Vanda Pharmaceuticals has received FDA acceptance for its Biologics License Application (BLA) seeking approval of imsidolimab as a treatment for…
Texas Instruments’ shares declined recently as investors adjusted expectations around the pace of recovery in its end markets. Despite positive…
